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ABSTRACT
Eukaryotic 5′ mRNA cap structures participate to the
post-transcriptional control of gene expression be-
fore being released by the two main mRNA decay
pathways. In the 3′-5′ pathway, the exosome gen-
erates free cap dinucleotides (m7GpppN) or capped
oligoribonucleotides that are hydrolyzed by the Scav-
enger Decapping Enzyme (DcpS) forming m7GMP. In
the 5′-3′ pathway, the decapping enzyme Dcp2 gener-
ates m7GDP. We investigated the fate of m7GDP and
m7GpppN produced by RNA decay in extracts and
cells. This defined a pathway involving DcpS, NTPs
and the nucleoside diphosphate kinase for m7GDP
elimination. Interestingly, we identified and charac-
terized in vitro and in vivo a new scavenger decap-
ping enzyme involved in m7GpppN degradation. We
show that activities mediating cap elimination iden-
tified in yeast are essentially conserved in human.
Their alteration may contribute to pathologies, pos-
sibly through the interference of cap (di)nucleotide
with cellular function.
INTRODUCTION
In eukaryotes, transcripts produced by RNA polymerase II
and by some viruses are cotranscriptionally modified by the
incorporation of a 5′ cap structure and, in most cases, by
addition of a 3′ polyA tail (1,2). The cap structure contains
minimally a guanosine methylated on position 7 attached
through a 5′-5′ triphosphate linkage to the first residue
of the transcript (m7G(5′)ppp(5′)N with N being the first
residue of the transcribed RNA). The cap structure can be
further modified by addition of other methyl groups on var-
ious positions, depending on the species (3–6). The mRNA
cap is a distinctive mark that allows cells to recognize bona
fide mRNA 5′ end and in some instances to discriminate
against transcript emanating from infectious genetic ele-
ments. This structure plays an essential role in the post-
transcriptional control of gene expression. In the nucleus, it
interacts with the cap binding complex and participates to
mRNA splicing, 3′ end maturation and nuclear export (7).
In the cytoplasm, the cap interacts with the eIF4F complex
playing a critical role in translation initiation (7). Finally,
the mRNA cap protects transcripts from degradation by
blocking access to exonucleases (8–10). mRNA turnover is
a tightly regulated process that allows cells to rapidly adapt
to environmental changes as well as to eliminate defective
transcripts. Bulk mRNA decay usually initiates with the re-
moval of the 3′ polyA tail (11). This rate-limiting step is
most often followed by cap removal (a process named de-
capping) that constitutes the first step of the 5′-3′ mRNA
decay pathway. Decapping is mostly performed by Dcp2
after stimulation by accessory factors. This Nudix protein
familymember hydrolyzesmRNAcaps to generatem7GDP
and 5′ monophosphorylated RNA (12–14). Additional en-
zymes have been shown to catalyze cap removal in vitro, in-
cluding several members of the Nudix protein family such
as Nudt16 (15,16) as well as Rai1 and Dxo1 (17,18). How-
ever, evidence that such proteins participate to cap removal
in cells has so far only been reported for Nudt16, a pro-
tein present in metazoan that also produces m7GDP (15). 5′
monophosphorylated RNAs produced by Dcp2 or Nudt16
are exonucleolytically digested by Xrn1 in the 5′ to 3′ di-
rection. Deadenylated mRNAs that are not subject to de-
capping enters the 3′-5′ mRNA decay pathway where the
mRNAbody is exonucleolytically degraded by the exosome.
When the exosome reaches themRNA5′ end, it releases free
cap dinucleotides (m7GpppN) and/or capped oligoribonu-
cleotides (19). Aberrant mRNAs are degraded by a variety
of pathways that are activated as a consequence of molec-
ular defects or distinctive features present in the transcript
(premature termination codon, abasic site, structure impair-
ing translation, absence of in frame stop codon, aberrantly
terminated cryptic transcripts etc.) (20–22). While initiated
by dedicated preliminary steps, these pathways invariably
lead to activation of decapping or 3′-5′ exonucleolytic diges-
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tion of the RNA and thus generate m7GDP or m7GpppN.
In vitro assays revealed that m7GpppN cap structures re-
sulting from exosome-mediated mRNA degradation were
further hydrolyzed in mammalian cell extracts by an ac-
tivity bored by DcpS (19,23). DcpS is a member of the
histidine triad (HIT) superfamily whose members contain
conserved histidines and hydrolyze nucleotide derivatives
(24,25). Mammalian DcpS, as well as its yeast homolog
Dcs1, form homodimers that cleave the m7GpppN dinu-
cleotides, or short capped oligoribonucleotides, between the
 and phosphates of the cap releasingm7GMP (19,23,26).
Several lines of evidence indicate that DcpS also inter-
acts with 5′-3′ mRNA decay. Hence, DcpS was reported
to facilitate 5′-3′ mRNA degradation in yeast and 5′-3′
miRNAdegradation inCaenorhabditis elegans (27,28), pos-
sibly through the stimulation of Xrn1 (28,29). Moreover,
m7GDP resulting from decapping by Dcp2 is converted
intom7GMPand downstreamby-products when incubated
in yeast extracts in a process dependent uponDcs1 (30). The
exact role of DcpS in this reaction is however controver-
sial because m7GDP was reported to be either a substrate
or a high affinity inhibitor of this enzyme using recombi-
nant proteins from yeast, human or C. elegans (23,30–33).
Consistent with a role in the degradation of cap structures
released by mRNA decay, Saccharomyces cerevisiae Dcs1
is principally cytoplasmic (31) but surprisingly DcpS accu-
mulates in the nucleus of Schizosaccharomyces pombe and
human cells (10,34). The latter observation could suggest
that it is mostly involved in degradation of cap structures
released by exosome-mediated degradation of capped nu-
clear RNA such as CUTs (20). Alternatively, m7GpppN
dinucleotides generated by cytoplasmic 3′-5′ degradation
diffuse to the nucleus before being hydrolyzed by DcpS.
Despite its clear activity catalyzing m7GpppN hydrolysis,
deletion of the dcs1 gene in yeast does not result in strong
growth phenotype (23,30). This suggests that accumulation
of m7GpppN dinucleotide in cells is not sufficient to im-
pact on cell growth in laboratory conditions or that an al-
ternate pathway to eliminate m7GpppN dinucleotide exists.
However beside Dcs1, only the Gag proteins from the virus-
like L-A and L-BC elements were reported to metabolize
m7GpppN in yeast (35). The facultative presence of the L-
A and L-BC elements argues against a critical role of this
mechanism in mediating m7GpppN elimination. DcpS ac-
tivity appears to be more relevant in higher eukaryotes as
demonstrated by the embryonic lethal phenotype in mice
harboring a homozygous disruption of the DcpS gene (36).
An inhibitor of DcpS was also reported to improve mice
conditions in a model of Spinal Muscular Atrophy (37),
suggesting that altering cap degradation may be a mean
to modulate pathological conditions. Quantitative estima-
tions of transcript abundances and half-lives indicate that
roughly 300–1200 molecules of m7GDP or m7GpppN are
generated every minute in exponentially growing yeast cells
(38,39) and 250 in mammalian cells (40,41). Accumulation
of such compounds could have deleterious effects on cells
as they have been reported to impact on many cellular pro-
cesses (36). Hence, high levels of m7GpppG inhibits in vitro
splicing of reporter RNA (42) as well as export of nuclear
RNA in vivo in Xenopus oocytes (43). m7GpppG also ac-
tivates deadenylation mediated by the PARN nuclease (44).
Similarly, high levels of m7GDP were reported to inhibit in
vitro translation and polysome formation (45). Moreover,
m7GDP could be converted into m7GTP or m7dGTP that
may potentially be incorporated in RNA or DNA. While
such residues are unlikely to alter the coding information
stored in nucleic acids, their presence may activate degrada-
tion or repair processes that could impact on cell fitness.
Altogether, these observations suggest that cells must ac-
tively eliminate cap derivatives liberated by RNA decay to
avoid the potential impact of such molecules. This issue has
been little explored. In Drosophila and human, 5′ nucleoti-
dases, CG3362 and cytosolic nucleotidase III-like respec-
tively, were shown to hydrolyze specifically m7GMP into
orthophosphate and m7G (46,47). These proteins have no
homologs in yeast, however, suggesting that alternative pro-
cesses exist. In yeast, m7GMP was also reported to be de-
phosphorylated by an unknown enzyme (23). However, in-
cubations of m7GMP in yeast extracts demonstrated that
it is transformed into by-products of unknown structures
(30). Because the eukaryotic pathways involved in elimina-
tion of cap derivatives are poorly understood and because
the role of DcpS in some steps of this process is controver-
sial, we decided to investigate the fate of m7GpppN and
m7GDP generated by RNA decay. We identified and char-
acterized new enzymes involved in cap degradation in vitro
and in vivo. Our results indicate that the process of elimina-
tion of cap structure derivatives generated byRNA turnover
is a complex process.
MATERIALS AND METHODS
Strains and plasmids
Oligonucleotides and strains used in this study are listed
respectively in Supplementary Tables S1 and S2. Deletion
of YNK1 or APH1 genes in the BMA64 strain was car-
ried out by homologous recombination. The YNK1 gene
was replaced byHIS3MX6marker that was amplified with
oligonucleotides OBS6090-OBS6091 carrying, a 45-nt long
region at their 5′ end, homologous to, respectively, the 5′ or
3′ termini of the YNK1 open reading frame (ORF). APH1
gene was replaced by LEU2marker that was amplified with
oligonucleotides OBS6240-OBS6241 carrying respectively
a 45-nt long region, at their 5′ end, homologous to the 5′
or 3′ termini of the Aph1 ORF. The resulting polymerase
chain reaction (PCR) fragments were transformed in the
wild-type yeast strain and the resulting colonies, growing
on the appropriate selective medium, were verified for dis-
ruption by PCR screening. The double or triple deletion
mutants were constructed by crosses and tetrads dissec-
tion. pBS2312 was used for expression of glutathione-S-
transferase (GST)-hDcp2–6His (13) and pBS2497 for GST-
DcpS6His (30). The GST-FHIT (fragile histidine triad pro-
tein) expression plasmidwas kindly provided byY.H.Wong,
(48). The pBS5051 expression plasmid contains the Aph1
coding sequence PCR-amplified from plasmid p19 kindly
provided by Plateau (49). The PCR product, obtained by
using oligonucleotidesOBS6510 andOBS6518was digested
with EcoRI and XhoI and cloned in EcoRI-XhoI digested
pBS5026, thus replacing the FHIT ORF. Absence of mu-
tations was verified by sequencing. The catalytic mutations
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were introduced using the Quickchange Mutagenesis strat-
egy. Oligonucleotides OBS6505-OBS6506 were used for
FHIT H96N mutation and OBS6507-OBS6508 for Aph1
H109N mutation. Recombinant proteins were expressed
and purified onGlutathione Sepharose 4B beads essentially
following the supplier recommendation (GE Healthcare).
Cell extracts preparation
For yeast total extracts, cells were collected in late exponen-
tial growth phase (OD around 0.81). The amount of cells
corresponding to a total of 200 optical density (OD) were
harvested andwashed twice respectively in 50ml of coldwa-
ter and 3 ml buffer A (10-mMHepes KOH pH 7.6, 10-mM
KCl, 1.5-mM MgCl2, 0.5-mM dithiothreitol (DTT), 0.5-
mM phenylmethanesulfonylfluoride (PMSF), 2-mM Ben-
zamidine, 1-MLeupeptin, 2-MPepstatin A, 4-MChy-
mostatin, 2,6-MAprotinin). Cells were resupended in 1ml
buffer A and cold glass beads (around 750 l; 0.5 mm di-
ameter BioSpec Products Cat. No. 11079105) were added.
Cell disruption was performed by vortexing at high speed
four times, each time 30 s at 4◦C.After disruption, cells were
centrifuged at 3000 g (Beckman JA-25.50 rotor) for 5 min
at 4◦C, 900 l of the supernatant were collected, mixed with
100 l of KCl 2M and centrifuged at 20 000 g in a Tabletop
Eppendorf centrifuge for 2min at 4◦C. The supernatant was
further centrifuged at 110 000 g for 20 min at 4◦C in TLA
120.2 rotor in Beckman TL-100 Tabletop Ultracentrifuge.
Supernatants were transferred in dialysis tubing (molecular
weight cut-off 12–14 000) and dialyzed two times, each time
for 60 min against 2 L cold buffer D (20-mM Hepes KOH
pH 7.6, 50-mM KCl, 0.2-mM ethylenediaminetetraacetic
acid (EDTA), 0.5-mM DTT, 20% glycerol, 0.5-mM PMSF,
2-mMBenzamidine). After dialysis, extracts were aliquoted
and stored at −80◦C. Human HEK293 cells were resus-
pended in buffer A and lysed in a dounce homogenizer.
After cell disruption, the extract preparation followed the
protocol described above. Protein concentrations of cleared
lysates were measured using the Bradford assay.
In vitro cap conversion assays
Cap-labeled RNA synthesis and in vitro decapping re-
actions were done as described (13). Reaction products
were separated by PEI cellulose thin layer chromatography
(TLC). The developing solution contained 0.3 M LiCl, 1 M
formic acid (except if otherwise specified). To obtain radio-
labeled m7GDP, and m7GpppG, cap-labeled RNA was in-
cubated with recombinant hDcp2 and nuclease P1 (Sigma-
Aldrich) respectively. For m7GMP synthesis, m7GpppG
was incubated with recombinant DcpS while to obtain
m7GTP, m7GDP was incubated with nucleoside diphos-
phate kinase (NDK) (Sigma-Aldrich) in presence of adeno-
sine triphosphate (ATP). The reaction products were sep-
arated by TLC and visualized with a PhosphorImager.
m7GMP, m7GDP, m7GTP or m7cap spots were scraped
off the TLC plate and eluted in decapping buffer (45-mM
Tris–HCl, pH 8, 27-mM (NH4)2SO, 49-mMMgAc) for 40
min at room temperature with constant shaking. Insoluble
TLCmaterial was removed by centrifugation. Product yield
was determined by counting. For activity assays 800 cpm of
m7GMP, m7GDP, m7GTP or m7cap were incubated with
500 ng of recombinant protein or 6 g of cellular extract
for 60 min at 30◦C in a 10 l final volume. Where specified
ATP (final concentration 2 mM), m7GpppG (final concen-
tration 10 M), 1 unit of NDK (Sigma-Aldrich), and/or
glucose (final concentration 5 mM) with 1 unit of hexok-
inase (Sigma-Aldrich) were added to the reactions. Reac-
tions were stopped by phenol-chloroform extraction. Five
microliters of such supernatants were analyzed by TLC us-
ing the conditions described above.
RNA electroporation
RNA was electroporated into yeast cell as described
previously (50) with slight modification. Briefly, cap-
labeled RNA (106 cpm/0.2 g) generated as indicated
above was electroporated into 100 l of yeast spher-
oblasts (108 cells/ml) resuspended in 1 M sorbitol.
Following discharge (800V/25 faraday/1000 Ohm;
Genepulser Bio-rad), cells were washed twice with yeast
extract/bactopeptone/dextrose (YPD) containing 1 M
sorbitol at room temperature, then resuspended in the same
medium and incubated at 30◦C with gentle swirling. Forty-
five minutes post-electroporation, cells were harvested,
washed and resuspended in decapping buffer, and lysed by
freezing–thawing in liquid nitrogen. The supernatant was
extracted twice with an equal mixture of phenol and chlo-
roform, and once with chloroform. Where indicated 2 g
of DcpS or 1 unit of NDK with ATP (final concentration
2 mM) where added to the lysate. The decapping products
fractionated by TLC and detected by autoradiography.
RESULTS
ATP- and Dcs1-dependent conversion of m7GDP into
m7GMP and generation of m7GDP from m7GpppG in yeast
extracts
To determine the fate of m7GDP and m7GpppG, we in-
cubated these compound radiolabeled on the  -phosphate
of the cap (i.e. the phosphate linked directly to the ribose
carrying the m7guanine group) in extracts derived from
wild-type or dcs1 mutant yeast cells. Reaction products
were fractionated by TLC alongside markers and detected
by autoradiography (Figure 1A). Consistent with a previ-
ous report (30), m7GDP incubated in wild-type extract was
efficiently transformed into m7GMP, an uncharacterized
m7GMP derivative named product X and free phosphate as
well as a few minor species (Figure 1A, lane 5). Conversion
of m7GDP into m7GMP and product X was abolished in
extracts prepared from dcs1 cells (Figure 1A, lane 6) con-
firming the requirement for this factor in the transformation
process (30). Interestingly, beside high levels of m7GDP, we
noticed the appearance of a slow-migrating species in such
reactions (Figure 1A, lane 6, compare with control reaction
lane 4). Co-migration with markers in different TLC sys-
tems identified this compound as m7GTP (Supplementary
Figure S1). Parallel reactions performed in buffer lacking
ATP demonstrated that a source of energy was required for
the conversion of m7GDP into m7GMP and product X in
extracts fromwild-type cells and ofm7GDP intom7GTP in
extracts prepared from  dcs1 cells (Figure 1A, lanes 1–3).
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Figure 1. m7GDP, m7GpppG and m7GMP conversion in yeast extracts. (A) Products resulting from the incubation of m7GDP or m7GpppG in various
yeast extracts were fractionated by TLC and detected by autoradiography. Purified radiolabeled m7GDP and m7GpppG were incubated with buffer (lanes
1, 4, 7, 10), or whole cell extracts from wild-type yeast (lanes 2, 5, 8, 11) or adcs1mutant (lanes 3, 6, 9, 12). In lanes 1 to 3 and 7 to 9 addition of ATP was
omitted. Lanes labeled M on the left contains molecular markers. Positions of migration of the various cap derivatives are indicated on the left. (B) TLC
analysis of m7GMP conversion products. Purified radiolabeled m7GMP was incubated with buffer (lanes 1 and 3), or whole cell extracts from wild-type
yeast (lanes 2 and 4). In lanes 1 and 2 addition of ATP was omitted. (C and D) Schemes indicating the fate of m7GDP and m7GpppG in extracts from
different strains.
Reactions with m7GpppG as substrate, originally designed
as controls, provided interesting insights. Hence, m7GpppG
was converted into m7GMP and product X both in the
presence and absence of ATP (Figure 1A, lanes 8 and 11).
This indicated that DcpS was active in both conditions and
that the lack of conversion of m7GDP into m7GMP ob-
served in the absence of ATP (Figure 1A, lane 2) did not
result from the lack of DcpS activity. Unexpectedly, how-
ever, we observed that m7GpppG incubated in Δdcs1 ex-
tracts was partly converted into m7GDP (Figure 1A, lanes
9 and 12). In the presence of ATP, a fraction of this com-
pound was also converted into m7GTP (Figure 1A, lane
12). Previous analyses had indicated that product X was
a metabolic derivative of m7GMP (30). This conclusion
was confirmed as purified m7GMP was converted in prod-
uct X in the absence and presence of ATP in extracts from
wild-type yeast cells (Figure 1B). Traces of downstream by-
products were detected in the presence of ATP (Figure 1B,
lane 4). As product X could be an intermediate in the recy-
cling ofm7GMP,we testedwhether enzymes involved in nu-
cleotide degradation and ribose salvage metabolism (Apt1,
Apt2, Npt1, Xpt1, Hpt1, Sdt1, Pnp1, Urh1, Phm8, Prm15,
Gud1, Lsn1) were implicated in its formation (51–53). In-
cubation of m7GMP in extracts prepared from cells lacking
the proteins, mentioned above, did not block product X for-
mation (data not shown). We also performed reactions us-
ing m7GMP labeled on its m7 group with tritium (Supple-
mentary Figure S2A). Counting the radioactivity present in
the different product bands revealed that this methyl group
was no more present in product X while control reactions
with P32 labeled substrates demonstrated that phospho-
rus was efficiently transferred from m7GMP to product X
(Supplementary Figure S2B). Altogether, these results con-
firmed that m7GDP is converted in m7GMP in a Dcs1-
dependent manner and that m7GMP is itself converted in
product X. Our experiments demonstrated further that the
transformation of m7GDP into m7GMP requires ATP and
that in extracts from dcs1 mutant cells m7GTP is formed
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in the presence of ATP (Figure 1C). Remarkably, we also
observed that m7GpppG, the end product of 3′-5′ mRNA
decay, was converted into m7GDP in extracts (Figure 1D).
Conversion of m7GDP into m7GMP requires the NDK en-
zyme to form an m7GTP intermediate
The requirement for ATP to convert m7GDP into m7GMP
and the accumulation of m7GTP in extracts lacking Dcs1
were consistent with the idea thatm7GTP could be an inter-
mediate in this pathway. Consistently, m7GDP is known to
be phosphorylated by theNDK intom7GTP in vitro (13,23)
while the latter was shown to be hydrolyzed into m7GMP
by recombinant Dcs1 (33). This suggested that NDK could
participate to the conversion of m7GDP in extract by phos-
phorylating it. To quickly provide support for this idea, we
tested whether various nucleoside triphosphate supported
this reaction as NDK is known to display little specificity
(54). The eight common (d)NTPs (nucleoside triphosphate)
promoted the conversion of m7GDP into m7GMP in ex-
tract from wild-type cells and the formation of m7GTP
in extracts lacking Dcs1 (Supplementary Figure S3A) sup-
porting the involvement of NDK. To further demonstrate
the implication of NDK in cap degradation, we constructed
a yeast strain lacking the dispensable ynk1 gene (55). By
crosses, we also built a strain lacking both ynk1 and dcs1.
Extracts prepared from these cells were tested for their abil-
ity to metabolize m7GDP. Consistent with our hypothesis,
conversion of m7GDP into m7GMP did not occur in ex-
tracts lacking NDK (Figure 2A, compare lanes 1, 2 and 4).
Moreover, the accumulation of m7GTP detected in extracts
deprived of Dcs1 (Figure 2A, lane 3) was abolished when
NDK was simultaneously absent (Figure 2A, lane 5). Im-
portantly, addition of purified NDK to these extracts re-
stored the conversion of m7GDP into m7GMP in ynk1
extract and the accumulation ofm7GTP indcs1ynk1 ex-
tracts while it had no effect on extracts prepared fromdcs1
or wild-type cells (Supplementary Figure S3B). By incu-
bating m7GTP in yeast extracts, we confirmed that it was
converted into m7GMP (Figure 2B, lane 2). This process
was blocked in extracts lacking Dcs1 (lane 3 and 5, some
m7GDP accumulates probably owing to the action of some
phosphatase present in the extract) but was unaffected by
the absence of ynk1 (Figure 2B, lane 4). Altogether, these
results demonstrate that NDK is required for the conver-
sion of m7GDP into m7GMP. These results reveal a bio-
chemical pathway for m7GDP elimination in extracts that
involves first its conversion in m7GTP mediated by NDK
in the presence of (d)NTPs followed by hydrolysis of the
m7GTP intermediate intom7GMPcatalyzed byDcpS (Fig-
ure 2C). This scheme is consistent with the accumulation of
m7GTP detected in the absence of DcpS (Figure 2A, lane
3).
The m7GDP elimination pathway is conserved in human
It was previously reported that m7GDP incubated in ex-
tracts from human cells or Xenopus oocytes was efficiently
converted into m7GMP with no evidence for further con-
version in product X (30). We thus tested whether the re-
action occurring in mammalian cell extract followed the
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Figure 2. Role of NDK encoded by the YNK1 gene if cap conversion
(A). TLC analysis of m7GDP conversion products. Purified radiolabeled
m7GDP was incubated with buffer (lanes 1), or whole cell extracts from
wild-type yeast (lane 2), a dcs1 mutant (lane 3), a ynk1 mutant (lane
4) or a dcs1ynk1 double mutant (lane 5). (B) Same as in (A) but the
substrate is m7GTP. All reactions were performed in presence of ATP. (C)
Scheme describing the biochemical pathway involved in m7GDP elimina-
tion in extracts.
steps that we identified for yeast by incubating m7GDP
in HEK293 cell extract under various conditions. In pres-
ence of ATP, the human cell extract efficiently transformed
m7GDP intom7GMP (Figure 3, lane 8) while when noATP
was added only a partial conversion was detected, some
m7GDP remaining after the reaction (Figure 3, lane 4). This
residual activity results from the presence of traces of ATP
in the extract as it was abolished when an ATP depleting
system was used (Supplementary Figure S4). This indicated
that like for yeast, ATP was required for the conversion of
m7GDP into m7GMP. To test whether DcpS was also in-
volved in this process, we relied on the observation that
DcpS can be inhibited by high levels of m7GpppG (56).
We incubated m7GDP in HEK293 cell extract in presence
of inhibitory concentration of unlabeled m7GpppG. This
treatment prevented the conversion of m7GDP and lead to
the accumulation of m7GTP (Figure 3 lane 12). A similar
result was obtained with extracts prepared from wild-type
yeast (Figure 3 lane 10)mimicking an extract prepared from
a dcs1 strain (Figure 3 lane 11). Altogether, these results
show that elimination of m7GDP in extracts from human
cells occurs with the same characteristics as its degrada-
tion in yeast extract, including requirement for ATP and
DcpS activity, and accumulation of m7GTP in the absence
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control yeast extracts, were fractionated by TLC and detected by autora-
diography. Purified radiolabeled m7GDP was incubated with buffer (lanes
1, 5 and 9), whole cell extracts fromwild-type (lanes 2, 6 and 10) anddcs1
(lanes 3, 7 and 11) yeast strains, or HEK293 cell extract (lanes 4, 8, 12).
Reactions contained ATP at a final concentration of 2 mM except in lanes
1–4. In lanes 9–12, cold m7GpppG was added to a final concentration of
10 M to inhibit DcpS. The positions of cap derivatives are indicated on
the left side and the left lane labeled M contains molecular markers.
of DcpS function. These data strongly argue that the path-
way identified in yeast is conserved in mammals and likely
other eukaryotes.
Aph1, a new scavenger decapping enzyme, hydrolyzes
m7GpppG into m7GDP
By incubating radiolabeled m7GpppG in yeast extract pre-
pared from  dcs1 cells we unexpectedly observed the for-
mation of a product that we identified as m7GDP (Fig-
ure 1A, lanes 9 and 12). The absence of ATP prevented
the conversion of the latter into m7GTP confirming further
the nature of this product and leading to a higher accu-
mulation (Figure 1A lane 9). A low level of m7GDP was
also present when a complete extract was used and this
was enhanced when Dcs1 was inhibited by the addition
of m7GpppG, indicating that this reaction also occurs in
wild-type yeast cells (Figure 1A, lane 8; Supplementary Fig-
ure S5). This activity was not reported earlier, possibly ow-
ing to the fact that m7GDP comigrates with m7GpppG in
the TLC system originally used (23) (Supplementary Fig-
ure S1). The activity converting m7GpppG into m7GDP
was sensitive to sodium dodecyl sulphate, EDTA and heat
inactivation (data not shown), implicating an enzyme. Bib-
liography searches identified some HIT family members,
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Figure 4. m7GpppG conversion in yeast extracts. A TLC analysis of
m7GpppG conversion products is presented. (A). Purified radiolabeled
m7GpppG was used as substrate. Products resulting from incubation with
buffer (lanes 1), or whole cell extracts fromwild-type yeast (lane 2), adcs1
mutant (lane3), a aph1 mutant (lane 4) or a dcs1aph1 mutant (lane
5) were analyzed. (B) Same as in (A) but cold m7GpppG was added to a
final concentration of 10 M to inhibit DcpS.
namely Apa1, Apa2 and Aph, as likely candidates to per-
form this reaction. Among them, Aph1 previously shown
to hydrolyze ApppN but also other dinucleotide prefer-
entially with a 5′-5′ triphosphate linkage (49) was a pri-
mary candidate. Testing for the fate of m7GpppG in ex-
tracts from strains carrying individual or multiple deletion
of these genes revealed that in conditions were Dcs1 was in-
hibited, formation of m7GDP did not occur in extracts pre-
pared from cells lacking Aph1 (Supplementary Figure S6).
To study the role of Aph1 in m7GpppG degradation, we
constructed a Δaph1 strain in our strain background. By
crosses, we also built an isogenic strain lacking both aph1
and dcs1. Extracts prepared from these cells were tested
for their ability to metabolize m7GpppG. Consistent with
our first result, in extracts prepared fromaph1dcs1 cells,
m7GpppG was no further hydrolyzed into m7GDP and
remained stable (Figure 4A, lane 5). In extracts prepared
from aph1 cells, m7GpppG was converted into m7GMP
and product X due to the activity of Dcs1 and down-
stream enzymes (Figure 4A, lane 4). m7GpppG hydroly-
sis was also prevented in extracts lacking Aph1 when Dcs1
was simultaneously inhibited by a high level of m7GpppG
(Figure 4B, lane 4) while under the same conditions for-
mation of m7GMP was strongly inhibited in an extract
from wild-type cells leading to increased accumulation of
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Figure 5. m7GpppG cleavage by recombinant Aph1 and FHIT. (A) Prod-
ucts resulting from the incubation of m7GpppG with recombinant pro-
teins were fractionated by TLC and detected by autoradiography. Puri-
fied radiolabeled m7GpppG was incubated with reaction buffer (lane 1),
or GST (lane 2), GST-FHIT (lane 3), a GST-FHIT catalytic mutant H96N
(lane 4), GST-Aph1 (lane 5), aGST-Aph1 catalytic mutantH109N (lane 6)
or as a control human DcpS (lane 7). All reactions contained 0.5 g of the
respective recombinant protein. (B) Purified protein profiles. Recombinant
GST:Aph1 and GST:FHIT and the respective catalytic mutants were pu-
rified and separated on sodium dodecyl sulphate-polyacrylamide gel elec-
trophoresis. Positions of migration of molecular weight markers are indi-
cated on the right side.
m7GDP (Figure 4B, lane 2). To demonstrate that Aph1 is
sufficient to perform this reaction, we expressed recombi-
nant glutathione-S-transferase (GST)-tagged Aph1 in Es-
cherichia coli (Figure 5B). Incubation of purified Aph1 with
m7GpppG resulted in the formation of m7GDP with only
traces of m7GMP present (Figure 5A, lane 5). As control,
nom7GDPproductionwas detectedwhen the substratewas
incubatedwith purifiedGST (Figure 5A, lane 2). To exclude
that the reaction was due to a contaminant, we constructed
and purified a Aph1 catalytic site mutant by exchanging
histidine 109 with asparagine (Figure 5B). m7GpppG in-
cubated with the mutant factor did not get significantly hy-
drolyzed intom7GDP (Figure 5A, lane 6). Altogether, these
results demonstrate that in yeast m7GpppG is degraded not
only by DcpS but also by a second scavenger decapping en-
zyme, Aph1 (Figure 5C). In contrast to the former, the latter
catalyzes the production of m7GDP.
The product of the human tumur suppressor gene FHIT cat-
alyzes cap cleavage
FHIT, the human homolog of Aph1 (49), is known as tu-
mor suppressor and its gene is deleted in many types of
cancers (57). Although many efforts were done to uncover
the molecular mechanisms leading to cancer suppression,
its molecular function remains poorly understood (25).
This member of the HIT family also harbors a dinucleo-
side polyphosphate hydrolase activity (58). To test whether
FHIT could also be involved in cap metabolism, we ex-
pressed GST-tagged recombinant FHIT (Figure 5B). Incu-
bation of the purified factor with m7GpppG leads to the
production of both m7GDP and m7GMP (Figure 5A, lane
3). We again verified that FHIT was directly involved in cat-
alyzing this hydrolysis by substituting the histidine 96 of
the FHIT catalytic site with an asparagine. The purified re-
combinant mutant protein (Figure 5B) was unable to cleave
m7GpppG (Figure 5A, lane 4). These results indicate that,
like its yeast homologue Aph1, FHIT is likely to be involved
in cap degradation.
In vivo analysis of m7G cap metabolism
The results presented above indicate that Dcs1 and Aph1
are involved in cap degradation in yeast extract. To test
whether these proteins affect the fate of cap structures re-
leased by RNA degradation in vivo in cells, we transformed
a 49-nt RNA in the different yeast strains by electropora-
tion. This artificial RNAwas radiolabeled on the phosphate
in position  of the cap structure. Forty-five minutes post-
electroporation, we extracted the cellular content and frac-
tionated it by TLC after protein inactivation and removal.
Several products, some comigrating with m7-containing
nucleotides and some of unknown identity, were detected
by autoradiography (Figure 6, lane 1). Control reactions
demonstrated that these products arose as a consequence of
RNA introduction in cells, as they were not detected when
no cells were present and when the radiolabeled RNA was
added after the electric pulse (data not shown). Interest-
ingly, in absence ofDcs1 (dcs1 and dcs1/ynk1 strains),
we observed the accumulation of m7GDP and, to a higher
extent, of a second productmigrating slightly faster (labeled
Ypp), as well as traces of m7GTP and m7GpppG (Figure 6,
lanes 3 and 4). Product Ypp is a nucleotide diphosphate as
in the presence of ATP it is a substrate of NDK (Figure 6
compare lanes 3–4 and 11–12). Moreover, product Ypp is
likely to be a derivative of m7GDP as it accumulates when
the m7GDP level rises (Figure 6) and as it is present after
electroporation of m7GDP in dcs1ynk1 cells (data not
shown). The accumulation of m7GDP and a downstream
derivative in dcs1 cells provides a direct evidence for the
role of Dcs1 in cap metabolism in vivo. Deletion of ynk1
encoding NDK had little effect on the product profile (Fig-
ure 6, compare lanes 1 and 2), probably because other en-
zymes are redundant with Ynk1. The same applied to a 
aph1 strain, consistent with the limited impact of the ab-
sence of Aph1 alone onm7GpppG breakdown in vitro (Fig-
ure 6, lane 5). Importantly, however, the simultaneous elim-
ination of Aph1 and Dcs1 lead to strong accumulation of
m7GpppG in cells (Figure 6, lane 6) with a slight reduction
in m7GDP levels. No further enhancement was detected
whenNDKwas simultaneously absent (Figure 6, lane 8). To
ascertain our identifications, we incubated purified recom-
binant Dcs1 protein in the lysate. This reaction confirmed
that m7GpppG accumulated in dcs1/aph1 electropo-
rated cells as this product was hydrolyzed into m7GMP
(Figure 5, compare lanes 6–8 and 22–24).
Taken together with our in vitro data, these results
demonstrate that Dcs1 and Aph1 are scavenger decapping
enzymes with overlapping actions mediating the elimina-
tion of m7GpppN residues and other cap by-products gen-
erated by mRNA decay in eukaryotic cells.
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Figure 6. m7G cap metabolism in living cells. An artificial 49 nt long capped RNA radiolabeled on the cap phosphate group in position  was electro-
porated in cells: wild-type (lane 1), ynk1 (lane 2), dcs1 (lane 3), dcs1ynk1 (lane 4), aph1 (lane 5), dcs1aph1 (lane 6) aph1ynk1 (lane 7) or
dcs1aph1ynk1 (lane 8) strains. After 45 min of incubation, the resulting metabolites were extracted, fractionated by TLC and detected by autoradio-
graphy. Products recovered from the strains above were incubated with 1 unit of NDK in presence of ATP (lanes 9–16) or 2 g of purified Dcs1 (lanes
17–24). The product resulting from the conversion of species Ypp by NDK (Yppp) is not resolved from m7GTP. The two TLC were developed in parallel
and exposed for the same duration.
DISCUSSION
The process of mRNA decay, driven by different enzymatic
activities, generates as endproduct nucleotides, that may di-
rectly serve for numerous cellular functions, as well as m7G
cap (di-)nucleotides. Quantification of the number of mR-
NAs per cells and of their average half-lives indicate that
hundreds of molecules of m7GDP and m7GpppN are gen-
erated every minute in yeast and mammalian cells (38–
41). The fate of cap structures has been only partly eluci-
dated with the identification of DcpS as an enzyme promot-
ing the conversion of m7GpppN in m7GMP (19,23) and
the identification of a nucleotidase that converts the latter
in m7guanosine in metazoans (46,47). Analyzing the fate
of cap (di)nucleotide, we identified and characterized new
scavenger decapping enzymes, Aph1/FHIT, that actively
convert m7GpppG into m7GDP (Figure 7) and demon-
strated that DcpS participates to the conversion of m7GDP
produced by the 5′-3′ pathway into m7GMP through an
m7GTP intermediate, both in yeast and mammalian cells.
As DcpS was reported to be essential for the degradation
of m7GpppG cap in extracts, we were surprised to ob-
serve an efficient conversion of m7GpppG in m7GDP in
lysates from yeast cells lacking the DCS1 gene. This re-
sult was highly reproducible and we explain that this path-
way was not detected earlier by a technical limitation of
the original TLC system used to follow the DcpS activity
(19,23). Indeed, in these conditions, m7GDP co-migrates
with m7GpppG (Supplementary Figure S1). Hence, inter-
conversion of these two products could not be detected.
Testing yeast strains mutant for several HIT family mem-
bers revealed that Aph1 is required to cleave m7GpppG
into m7GDP. This is consistent with its ability to cleave din-
ucleotide triphosphate reported in the literature. Further
analyses performed with the recombinant Aph1 protein
demonstrate that this enzyme cleavesm7GpppG to generate
m7GDP. In vivo analyses, importantly, confirm the implica-
tion of bothAph1 andDcpS in cap breakdown in yeast cells.
The synergic effect ofAPH1 andDCS1 deletions shows fur-
ther that they have overlapping role in the degradation of
m7GpppG under normal physiological conditions. The cap
scavenging activities of Aph 1 and Dcs1 are not shared with
other HIT family members. Indeed, in the double mutant
aph1 dcs1m7GpppG accumulates indicating that other
HIT protein still present in the extract do not efficiently hy-
drolyze this product. The observation that the double mu-
tant strains grow relatively well may be accounted for by the
fact that 3′-5′ mRNA decay is not the major route to elimi-
nate mRNAs. Consistently, mutations abolishing the activ-
ity of the Ski complex (Ski2/3/8) or of Ski7, factors that
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Figure 7. RNA decay pathways and cap (di-)nucleotide elimination mech-
anisms in yeast and mammalian cells. Enzymes involved in the generation
of cap (di-)nucleotide in the 5′-3′ and 3′-5′ mRNA decay pathways are in-
dicated as well as the resulting products. Mechanisms mediating the elimi-
nation of these compounds identified in this study are indicated with yeast
enzymes indicated in blue and human factors in red. Degradation of the
end-product m7GMP by cNIII was reported earlier (46).
are specifically involved in the 3′-5′ degradation of mRNAs,
also result in no or limited growth phenotypes. Interestingly,
the product of the human tumor suppressor gene FHIT, a
homolog of Aph1, also cleaves m7GpppG but produces a
mixture of roughly 50%m7GMPand 50%m7GDP.The dif-
ference in product composition can be explained by the abil-
ity of FHIT to recognize both bases of the m7GpppG din-
ucleotide, namely m7guanine and guanine, thus being able
to bind this pseudo-symmetrical substrate in two orienta-
tions. In contrast, yeast Aph1 appears to productively bind
m7GpppGessentially in a single orientation, thus leading to
the formation of an essentially homogeneous products. The
observation that Aph1 participates to the elimination of cap
structures in vitro and in vivomay provide some hints about
the function of its human homolog FHIT. The gene encod-
ing for FHIT is located in the fragile site FRA3B on the
chromosome 3 and was found deleted in many type of can-
cers (59). FHIT acts as a proapoptotic factor inhibiting un-
controlled cell proliferation through an elusive mechanism
(25). Like some other HIT family members, FHIT hydroly-
ses diadenosine polyphosphates (58). The observation that
Aph1 contributes to the clearance of cap structures com-
bined with ability of FHIT to hydrolyze m7GpppG, sug-
gest that FHIT may contribute to cell growth control by
binding to m7GpppG, mediating the formation of down-
stream products and/or impacting on mRNA decay. It will
be important to investigate these possibilities in the future.
Our analyses of the fate of m7GDP incubated in extracts
revealed that it is converted into m7GMP in a two-step pro-
cess that appears to be conserved between yeast and human
cells. m7GDP is first transformed into m7GTP that is itself
metabolized intom7GMP (Figure 7). Traces of ATP (or any
other (d)NTP) present in extractsmay have impaired the de-
tection of the first of these steps previously (30). Under our
conditions, NDK appears to be the main enzyme catalyzing
m7GTP formation in yeast extracts. However, the absence
of growth phenotype of yeast cells lacking the gene encod-
ing NDK indicates the existence of other enzyme(s) con-
verting nucleoside diphosphate into triphosphate. Those
may also catalyze the conversion of m7GDP into m7GTP
in living cells. m7GTP is then hydrolyzed into m7GMP by
DcpS. These observations reconcile previous studies that
had argued for, or against, the involvement of DcpS in
m7GDP turnover (23,30,31,33). Consistent with the two-
step pathway that we identified, we observed the accumu-
lation of products co-migrating with m7GTP and m7GDP
(and the Ypp derivative) indcs1 cells transfected with cap-
labeled RNA. Previous analyses following electroporation
identified m7GpppG andm7GpppGp as products accumu-
lating in Δdcs1 cells (23). This difference may be accounted
for by the fact that in these earlier analyses, metabolites
present in the cells were analysed 6 h postelectroporation
and may thus represent indirect or late conversion prod-
ucts. It remains nevertheless difficult to reconcile them with
the presence of active Aph1. An alternative interpretation
is that their identity was incorrectly assigned. Our observa-
tion of the specific presence of m7GTP and m7GDP (and
its Ypp derivative) at early time points after electroporation
inΔdcs1 cells argues for a physiological role of this factor in
cap metabolism in vivo in a manner consistent with its bio-
chemical activities. The m7GMP originating from the 3′-5′
or 5′-3′ pathways is converted into a product of uncharacter-
ized structure (X) in yeast extracts, as previously reported.
Using radioactive labels on different groups of m7GMP, we
observed that the methyl group located on position 7 of the
guanosine is not present in product X. This suggests that
transformation of m7GMP in product X could minimally
be a demethylation. However, more complex reaction such
as those severing of the base-ribose bond or the transfer of
the phosphate group to a recipient molecule can’t yet be ex-
cluded. Altogether, our results reveal the existence of a com-
plex multistep pathway mediating the elimination of cap
structures arising as a consequence ofmRNAdecay (Figure
7) and suggest that it may impact in human cell physiology.
Further analyses will be necessary to uncover how altered
cap metabolism affect cell metabolism and how this drives
disease development.
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